Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
NCT00800280
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- healthy
- male or female adults
- Current or history of clinically significant medical illness
- Smokers
- Illicit drug use
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New Haven, Connecticut
- New Haven, Connecticut
- Orlando, Florida
- Prairie Village, Kansas
- Birmingham, Alabama
- Litchfield Park, Arizona
- Arcadia, California
- Beverly Hills, California
- Costa Mesa, California
- Costa Mesa, California
- Encino, California
- Escondido, California
- Murrieta, California
- National City, California
- Newport Beach, California
- Orange, California
- Pasadena, California
- Redlands, California
- San Diego, California
- San Diego, California
- Sherman Oaks, California
- Temecula, California
- Upland, California
- Wildomar, California
- Denver, Colorado
- Hamden, Connecticut
- Norwich, Connecticut
- Altamonte Springs, Florida
- Ft. Myers, Florida
- Jacksonville, Florida
- Maitland, Florida
- Miami, Florida
- Miami, Florida
- Orange City, Florida
- Orlando, Florida
- South Miami, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Marietta, Georgia
- Libertyville, Illinois
- Naperville, Illinois
- Park Ridge, Illinois
- Greenwood, Indiana
- Terre Haute, Indiana
- Overland Park, Kansas
- Prairie Village, Kansas
- Wichita, Kansas
- Owensboro, Kentucky
- Lake Charles, Louisiana
- Baltimore, Maryland
- Belmont, Massachusetts
- Boston, Massachusetts
- Fall River, Massachusetts
- Haverhill, Massachusetts
- Pittsfield, Massachusetts
- Omaha, Nebraska
- Las Vegas, Nevada
- Nashua, New Hampshire
- Albuquerque, New Mexico
- Bronx, New York
- Brooklyn, New York
- New York, New York
- New York, New York
- New York, New York
- Rochester, New York
- Raleigh, North Carolina
- Columbus, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Toledo, Ohio
- Bethany, Oklahoma
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Portland, Oregon
- Salem, Oregon
- Allentown, Pennsylvania
- Media, Pennsylvania
- Norristown, Pennsylvania
- Philadelphia, Pennsylvania
- Lincoln, Rhode Island
- Columbia, South Carolina
- Memphis, Tennessee
- Memphis, Tennessee
- Austin, Texas
- Dallas, Texas
- Dallas, Texas
- DeSoto, Texas
- Houston, Texas
- Houston, Texas
- Lake Jackson, Texas
- San Antonio, Texas
- Woodstock, Vermont
- Charlottesville, Virginia
- Seattle, Washington
- Middleton, Wisconsin
- Waukesha, Wisconsin
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body | |||
Official Title ICMJE | A Phase 1, Open-Label, Randomized, Cross-Over Study To Estimate The Effects Of Steady-State Cimetidine On The Pharmacokinetics Of A Single Dose Of PD 0332334 In Healthy Subjects | |||
Brief Summary | The purpose of this study is to estimate the effects of multiple doses of cimetidine on the pharmacokinetics of a single dose of PD 0332334 and to evaluate the safety and tolerability of PD 0332334 when co-administered with cimetidine. | |||
Detailed Description | Detailed Description: Additional Study Purpose Details: Evaluate the effects of multiple doses of cimetidine on the pharmacokinetics (e.g., elimination from the body) of a single dose of PD 0332334. On February 18th 2009, a decision to terminate further development for PD 0332334 was communicated to investigators in this study. The decision to terminate this study was not based on any safety concerns. | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) | |||
Condition ICMJE | Generalized Anxiety Disorder | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 12 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | February 2009 | |||
Actual Primary Completion Date | February 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 55 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00800280 | |||
Other Study ID Numbers ICMJE | A5361030 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | February 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |